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Are Omega-3 Fatty Acids
Ineffective for Preventing
Atrial Fibrillation Recurrence?
We read with great interest the paper by Macchia et al. (1). The
FORWARD (Randomized Trial to Assess Efficacy of PUFA for
the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation)
trial involving 586 participants with symptomatic atrial fibrillation
(AF) who already recovered normal sinus rhythm before being
included in the study. There was no significant difference between
the patients randomized to placebo or to omega-3 fatty acids for
symptomatic recurrence of AF. The authors concluded that sup-
plementation with 1 g of omega-3 fatty acids for 1 year did not
reduce recurrent AF.
Are omega-3 fatty acids really ineffective for the prevention of
atrial fibrillation recurrence? A meta-analysis indicated that in
patients (3 studies and 485 patients) administered omega-3 fatty
acids at least 4 weeks before cardioversion and continued thereaf-
ter, the recurrence rate of AF was obviously low (2). Metcalf et al.
(3) demonstrated omega-3 fatty acids incorporated into human
atrial cell membrane and reached a peak at about 30 days of
treatment. Though omega-3 fatty acids can be increased in plasma
and atrial tissue in short-term application, the concentration may
be insufficient to develop the best antiarrhythmic effect (4).
However, the patients in the FORWARD study were given
omega-3 fatty acids started after cardioversion. So, maybe the
duration of application before cardioversion is vital for its role.
Therefore, on the basis of current evidence we still can not reach
a definite conclusion whether omega-3 fatty acids is effective for
AF recurrence. Future large-scale, high-quality studies with pa-
tients being given omega-3 fatty acids at least 4 weeks prior to
cardioversion are needed to verify our speculation and give a
comprehensive evaluation of omega-3 fatty acids.
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Reply
We appreciate the letter of Dr. Guo and colleagues in which they
raised doubts about if we can be definitive in closing the debate
regarding the lack of efficacy of polyunsaturated fatty acids (n-3
PUFA) for the prevention of atrial fibrillation (AF). The authors
raised an important and legitimate concern mentioning that
omega-3 fatty acids may require time to be effectively in-
corporated into human cell membrane. Small systematic reviews
seem to confirm this fact (1).
However, we still think that oral supplementation with n-3
PUFA is ineffective for at least 2 reasons. First, our updated and
large systematic review that included 1,990 patients and 894 events
(2) failed—in a meta-regression analysis—to find any association
between supplementation and AF relapse, and disproved any
relationship among dose amount, time of loading, or use of other
antiarrhythmic therapies. Second, patients in the FORWARD
(Randomized Trial to Assess Efficacy of PUFA for the Mainte-
nance of Sinus Rhythm in Persistent Atrial Fibrillation) trial (3)
who received more than 30 days of “loading dose” of n-3 PUFA
(those who did not have a recurrence within the first month of
follow-up) presented the same rate of AF recurrence than those
who did not receive omega-3.
In any case, we cannot affirm that a large and “definitive”
clinical trial should not be conducted. However, we think
that—in the context of secondary prevention of AF—we do
have now strong evidence suggesting that oral supplementation
should not be initiated to prevent AF relapse. On the other
hand, this hypothesis is still untested in the setting of primary
prevention of AF. In this context, large clinical trials may be
conducted.
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The True Incremental
Cost of ECG Screening:
The Price Is Not Right,
But the Cost Appears Effective
In their analysis of the economic impact of the Italian electrocar-
diography (ECG) screening program for competitive athletes (1),
Halkin et al. (2) concluded that the cost in the United States over
a 20-year period would range from $51 to $69 billion. Assuming
that the program would be expected to save 4,813 lives (1), they
alculated a cost per life saved of $10.6 to $14.4 million. However,
he methods and assumptions used significantly inflate the cost of
CG screening. First, while the title describes the cost of “ECG
creening,” the figures provided for history and physical range from
224 to $313/athlete/year, and the estimates for ECGs range from
39 to $47/athlete/year. Thus, the ECG represents just 15% to
8% of the combined price, while the history and physical,
urrently recommended by the American Heart Association (3)
omprise 75% of the total, even accounting for subsequent addi-
ional testing. Determining cost effectiveness of the ECG compo-
ent requires estimating the incremental cost and incremental
enefit of the ECG, which was not done. Next, while the paper’s
itle describes the “cost,” the figures used are actually “prices,”
hich may not reflect the true costs based on actual payments and
iscounts negotiated for large screening programs.
The authors also justify reporting “cost per life saved” rather than
he more common “cost per year of life saved” because the lifespan of
he individuals saved is uncertain. However, most patients with
ypertrophic cardiomyopathy, the most common cause of sudden
ardiac death (SCD) in the young, live normal or near-normal
ifespans (4), as do those with most of the conditions leading to SCD
n young athletes. Failure to adjust for estimated lifespans is a major
ethodological limitation of this analysis. If these teenagers went on
o live normal lifespans, the cost per year of life saved becomes
$200,000, even using the overall prices in this analysis. Finally, the
osts are based on yearly screening as used in Italy (1). A prior cost
nalysis, also based primarily on the Italian study but using a 1-time
creen, found a cost effectiveness of $76,100 per year of life saved for
he combination of history and physical and ECG, with the incre-
ental cost effectiveness of the ECG $42,900 (5), well within the
ocietally accepted range. While the optimum frequency of screening
s unknown, ECG screening programs performed at less frequent
ntervals have also saved lives (6). Biennial ECG screening has beenuggested as an alternative. Because the ECG increases sensitivity,
ther studies have found the addition of the ECG improves cost
ffectiveness over history and physical alone (7).
To recommend abandoning screening in favor of improving
esuscitation is not the best formula for progress. Screening linked
o research will refine our knowledge of the best application of the
ools available. Furthermore, population-based studies show that the
ate of survival from sudden cardiac arrest remains10% (8,9). While
e strongly support basic and clinical research into resuscitation, as
ell as community preparedness efforts (9), the combination of
revention and intervention offers more opportunities to save lives
han either alone, as has been suggested from analyses of coronary
eart disease deaths (10).
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